Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus epacadostat versus pembrolizumab plus placebo in unresectable or metastatic melanoma
NL-OMON45831Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Nov 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and epacadostat in melanoma and cutaneous malignancy, sponsored by Incyte. Primary endpoints: Progression-free survival and Overall survival. Started Nov 2016; status: active, not recruiting.
02
Drugs
pembrolizumabepacadostat
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON45831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45831.